1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Deltex Medical Group plc

Deltex Medical Group plc

DTXMF
Deltex Medical Group plcUS flagOther OTC
0.10
USD
- -
- -
180.58MMarket Cap
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
Revenue per Share
0.05
0.05
0.04
0.03
0.03
0.02
0.02
0.01
0.01
- -
- -
- -
- -
Basic EPS, GAAP
-0.01
-0.01
-0.01
-0.02
-0.02
-0.01
-0.01
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.3
-0.29
-0.27
-0.24
-0.23
-0.19
-0.18
-0.1
-0.1
-0.09
-0.09
-0.07
-0.04
Tangible Book Value per Share
0.01
0.01
0.01
0.02
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
137
148
164
195
217
270
301
471
510
526
581
685
1,181
Sales/Revenue/Turnover
6
7
7
7
6
6
6
5
4
2
2
2
2
Operating Margin (%)
-22.24
-30.66
-29.34
-45.95
-52.04
-37.42
-32.91
-21.33
2.37
-38.53
-38.16
-39.44
-48.31
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-1
-2
-2
-3
-3
-2
-2
-1
- -
-1
-1
-1
-1
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-22.54
-30.88
-29.45
-45.35
-54.02
-37.53
-34.09
-25.51
-3.74
-32.74
-42.76
-46.17
-72.18
Working Capital
2
2
2
4
-1
1
- -
1
1
1
- -
- -
1
LT Debt
1
1
1
1
- -
1
1
1
1
1
1
1
2
Total Equity
2
2
3
5
2
2
1
2
3
3
2
2
3
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.78%
8.22%
41.07%
Free Cash Flow
26.45%
54.8%
78.11%
Net Income, GAAP
33.33%
71.97%
11.87%
Sales/Revenue/Turnover
-11.67%
-16.43%
-28.44%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
2
2023
- -
- -
- -
- -
2
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Natalie Emilia Wettler
Full Time Employees
24
Sector
Healthcare
Industry
Medical - Devices
Address
Terminus Road Chichester United Kingdom PO19 8TX
IPO Date
Dec 3, 2009
Website
deltexmedical.com
Similar Companies
Acutus Medical, Inc. (AFIB)
Medical Supply International USA, Inc. (MSIU)
Titan Medical Inc. (TMD.TO)
Viveve Medical, Inc. (VIVE)
CONMED Corporation (CNMD)
Paxman AB (publ) (PXMBF)
Business
Deltex Medical Group plc is a United Kingdom-based medical technology company that develops, manufactures and markets advanced haemodynamic monitoring systems for fluid management in surgical and critical care settings. The company offers oesophageal Doppler monitoring (ODM) products including the flagship TrueVue platform with ODM+, CardioQ-EDM and CardioQ-EDM+ probes that use ultrasound to measure aortic blood flow in real time; additional technologies such as Doppler probes, HD impedance cardiography, cerebral oximetry and laryngoscopes; and third-party products distributed alongside its core offerings to support minimally invasive monitoring that reduces complications like acute kidney injury and surgical site infections. Founded in 2000 and headquartered in Chichester, West Sussex, Deltex Medical operates through subsidiaries in the USA, Canada and Spain, with distribution in over 30 countries targeting anaesthetists, critical care clinicians and hospitals worldwide. Recent developments include the launch of the enhanced TrueVue system featuring improved signal acquisition, intuitive HD touchscreen software, integrated battery for portability and combined monitoring modes to broaden clinical applications; alongside a director change with the termination of Benjamin Edward Carswell in July 2025 and ongoing evidence-based adoption supported by endorsements from NICE, AHRQ and CMS reimbursement decisions.

Company News

APIChatGPT